Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

BACKGROUND/AIMS: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate the association between early infliximab trough levels and treatment outcomes of CT-...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jihye, Cheon, Jae Hee, Lee, Kang-Moon, Kim, Young-Ho, Ye, Byong Duk, Eun, Chang Soo, Kim, Sung Hyun, Lee, Sun Hee, Lee, Joon Ho, Schreiber, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191793/
https://www.ncbi.nlm.nih.gov/pubmed/35975641
http://dx.doi.org/10.5009/gnl220005

Ejemplares similares

Ejemplares similares